SB 1376 amends Business and Professions Code Section 3508 to delete the current requirement that the Physician Assistant Board obtain permission from the Director of Consumer Affairs to hold more than six meetings in a calendar year and that the director approve meetings deemed necessary for the board to fulfill its responsibilities. The bill leaves intact the board’s authority to convene as it deems necessary and the two‑week advance notice requirement for meetings.
The change shifts scheduling authority and meeting control away from departmental oversight and toward the board itself. That can speed regulatory work and responsiveness to emerging issues, but it also raises implementation questions about staff capacity, fiscal impacts for increased meeting frequency, and how the state will preserve accountability and public access when the director’s formal approval role is removed.
At a Glance
What It Does
The bill removes the statutory requirement that the Director of Consumer Affairs authorize more than six annual meetings of the Physician Assistant Board and delete the director’s duty to approve meetings necessary to fulfill the board’s legal responsibilities. The board retains its authority to convene as it sees fit and must continue to give at least two weeks’ notice of meetings.
Who It Affects
Directly affects the Physician Assistant Board, the Department of Consumer Affairs (and its Director), physician assistants regulated by the board, and organizations that regularly monitor or participate in board meetings (trade associations, patient advocates, legal counsel). Indirectly affects state staff who provide administrative, legal, and logistical support for board meetings.
Why It Matters
By removing a centralized approval gate, the bill increases board autonomy and could accelerate rulemaking, disciplinary scheduling, and stakeholder engagement; at the same time, it transfers operational burden and any resulting costs to the board and DCA staff and reduces a centralized check intended to manage meeting frequency and resource use.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Section 3508 currently has three elements: a grant of authority letting the Physician Assistant Board convene when it deems necessary, a two‑week advance notice rule for interested parties, and a separate sentence that requires the board to get permission from the Director of Consumer Affairs to exceed six meetings per year, with the director charged to approve meetings necessary for the board to meet its obligations. SB 1376 removes that last sentence.
After the amendment, the statutory picture will be: the board may convene as it deems necessary and must provide at least two weeks’ notice to interested parties; there is no longer a statutory cap tied to director approval.
In practice, the bill changes who controls meeting frequency. The board will no longer need to seek or obtain a director’s sign‑off to schedule more than six sessions, eliminating a formal administrative gate.
That reduces one layer of bureaucratic friction that can slow down recurring or emergency scheduling — for example, additional disciplinary hearings, rulemaking workshops, or ad hoc working sessions on emerging clinical practice issues.Operationally, the change is modest in text but material in effect. The Department of Consumer Affairs and the board will still perform the same logistical functions—venue reservations, staff briefings, legal counsel attendance, notice postings, and transcribing minutes—but without a statutory permission step they may need new internal controls to manage meeting load and costs.
The bill contains no appropriation, so any material increase in meeting frequency would have to be absorbed within existing budgets or addressed through separate budget action. Finally, the bill does not alter California’s open‑meetings rules or the two‑week notice requirement, so public access and advance notice obligations remain the primary statutory safeguards for participation and transparency.
The Five Things You Need to Know
SB 1376 deletes the sentence in Business and Professions Code §3508 that requires the Director of Consumer Affairs to permit the Physician Assistant Board to meet more than six times a year and to approve meetings necessary for the board to fulfill its duties.
The board’s authority to convene when it deems necessary (the grant of meeting authority) remains unchanged.
The two‑week advance notice requirement for meetings remains in place; the bill does not change public‑notice timing.
The bill contains no appropriation; the legislative digest flags a fiscal committee referral, indicating the Legislature seeks analysis of state cost implications but provides no direct funding in the bill text.
The change removes a formal layer of departmental approval but does not modify other legal requirements that govern board conduct, such as public‑meeting statutes and existing licensing or disciplinary procedures.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Board authority to convene
Subsection (a) continues to authorize the Physician Assistant Board to convene whenever the board deems it necessary. Practically, this provision is the statutory source of the board’s self‑scheduling power; the bill leaves that language intact so the board’s baseline authority to meet is unchanged.
Advance notice requirement
Subsection (b) remains the statutory notice rule: the board must give at least two weeks’ notice to persons and organizations that request notification. This preserves the principal transparency mechanism for public participation and stakeholder monitoring, meaning that even if meetings become more frequent, affected parties retain a predictable window to prepare and attend.
Removal of director approval for meetings beyond six per year
The deleted text required the board to obtain the Director of Consumer Affairs’ permission to meet more than six times annually and directed the director to approve meetings necessary to fulfill the board’s responsibilities. Eliminating that provision removes a statutory constraint and an administrative approval step. The practical implications are twofold: scheduling becomes more board‑driven, and the Department of Consumer Affairs loses a formal statutory lever to limit meeting frequency — though the department can still manage workloads via internal policies, budget controls, and department‑level oversight mechanisms.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Physician Assistant Board — Gains scheduling autonomy, enabling faster convening for rulemaking, disciplinary panels, or emerging clinical guidance without seeking director approval.
- Physician assistants and patients — Potentially benefit from quicker board responses to urgent issues, policy updates, or disciplinary actions because meetings can be scheduled more flexibly.
- Stakeholder organizations (professional associations, patient advocates) — May find increased opportunities for engagement and comment if the board holds more meetings or topical workshops.
Who Bears the Cost
- Department of Consumer Affairs staff — Administrative, legal, and logistical support workloads may rise if meeting frequency increases without dedicated new funding.
- State budget authorities — Any significant growth in meeting-related expenses (staff overtime, venue costs, transcription, IT for hybrid meetings) would need to be absorbed in existing budgets or covered by separate appropriations.
- Board members and regulated parties — More frequent meetings can increase time commitments for board members, witnesses, and counsel, raising participation costs for individuals and organizations.
Key Issues
The Core Tension
The bill trades centralized administrative control for board flexibility: giving the Physician Assistant Board freedom to set its meeting schedule boosts agility and responsiveness but shifts operational costs and accountability burdens onto the board and departmental staff — creating a classic trade‑off between autonomy and centralized oversight.
The bill is procedurally narrow but operationally consequential. Deleting the director‑approval requirement solves a scheduling friction point but replaces it with several implementation questions.
First, logistics and costs: nothing in the text provides additional funding for extra meetings. If the board increases meeting cadence, DCA will either reallocate existing resources or request supplemental funding — outcomes that affect other programs.
Second, accountability and oversight: removing a formal approval step reduces centralized control, but it does not eliminate other oversight levers (budget review, audits, or statutory duties). Stakeholders may perceive a decline in centralized checks unless the board and DCA adopt compensating transparency practices.
Third, legal and procedural ambiguity: the bill deletes the specific authorization language but leaves open how DCA’s internal policies, administrative codes, or interagency memoranda of understanding will adapt; those instruments will govern day‑to‑day practice until updated.
Additional unresolved issues include whether more frequent meetings will change the board’s cadence for quasi‑judicial functions (disciplinary panels) and whether frequent, shorter meetings or ad hoc working groups will become the norm. Increased frequency could improve responsiveness but also fragment agendas, stretch staff capacity thin, and reduce the depth of deliberations if not managed carefully.
Finally, while the two‑week notice remains, higher meeting volume may create stakeholder engagement fatigue; public notice does not guarantee meaningful participation if meetings proliferate unpredictably.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.